Outcome of elderly patients with DLBCL failing R-CHOP: The role of rituximab and high dose therapy in second line treatment. A retrospective analysis from the RICOVER 60 trial

Category Primary study
JournalBlood
Year 2009
This article has no abstract
Epistemonikos ID: d882d72ee7a3f3de01fdfc20be6c42dd2a475189
First added on: Mar 01, 2025